A Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 01 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Secukinumab (Primary) ; Nonsteroidal anti-inflammatories
Indications Rotator cuff injuries
Focus Therapeutic Use
Sponsors Novartis Pharmaceuticals

Most Recent Events

24 Feb 2025 Status changed from active, no longer recruiting to discontinued. (Reason the study was stopped: Project discontinued to prioritize other key programs in portfolio)
12 Jul 2024 Planned primary completion date changed from 8 Oct 2024 to 9 Oct 2024.
25 Jun 2024 Planned End Date changed from 16 Dec 2024 to 4 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight